Gilteritinib hemifumarate
≥99%
- Product Code: 100636
CAS:
1254053-84-3
| Molecular Weight: | 610.75 g./mol | Molecular Formula: | C₂₉H₄₄N₈O₃₀₅C₄H₄O₄ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8℃ |
Product Description:
Gilteritinib hemifumarate is primarily used in the treatment of relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. It functions as a FLT3 inhibitor, targeting and blocking the activity of the FLT3 receptor tyrosine kinase, which is often mutated in AML patients. This inhibition helps to slow down or stop the growth of cancer cells.
It is administered orally, allowing for convenient outpatient treatment. The drug is particularly beneficial for patients who have not responded well to other therapies, offering a targeted approach to managing the disease. Clinical trials have demonstrated its efficacy in improving survival rates and inducing remission in a significant proportion of patients with FLT3-mutated AML.
Regular monitoring of patients is essential to manage potential side effects, which may include liver function abnormalities, muscle pain, and fatigue. Overall, it represents a significant advancement in the targeted therapy of AML, providing hope for patients with this challenging condition.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | $426.09 |
+
-
|
| 0.010 | 10-20 days | $681.74 |
+
-
|
Gilteritinib hemifumarate
Gilteritinib hemifumarate is primarily used in the treatment of relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. It functions as a FLT3 inhibitor, targeting and blocking the activity of the FLT3 receptor tyrosine kinase, which is often mutated in AML patients. This inhibition helps to slow down or stop the growth of cancer cells.
It is administered orally, allowing for convenient outpatient treatment. The drug is particularly beneficial for patients who have not responded well to other therapies, offering a targeted approach to managing the disease. Clinical trials have demonstrated its efficacy in improving survival rates and inducing remission in a significant proportion of patients with FLT3-mutated AML.
Regular monitoring of patients is essential to manage potential side effects, which may include liver function abnormalities, muscle pain, and fatigue. Overall, it represents a significant advancement in the targeted therapy of AML, providing hope for patients with this challenging condition.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :